#Spain #Madrid #Suanfarma #Pere Mañé #API Industry

Pere Mañé Takes Charge as CEO of Suanfarma

In a significant development for the pharmaceutical industry, Pere Mañé Godina has been appointed as the new Chief Executive Officer (CEO) of Suanfarma, a global leader in the development, production, and marketing of active pharmaceutical ingredients (APIs) and high-value services for the health sector. His appointment is set to mark a transformative phase for the company, with a strong focus on industrial consolidation, sustainable innovation, and international growth.

Pere Mañé brings over three decades of experience in the pharmaceutical sector, having held various strategic and technical leadership roles in prominent companies such as Uquifa, Boehringer Ingelheim, and Esteve Group. His diverse career encompasses technical and operational roles, along with executive positions, including General Manager and Group Chief Industrial Operations Officer. Recently, Mañé was pivotal in the industrial transformation of Esteve, establishing its chemical division as a global reference point. He also led Esteve to win the award for CDMO of the Year – Small Molecules at the 2025 DCAT Leadership Awards, a prestigious honor in the industry.

Mañé's vision aligns with Suanfarma's long-term strategic goals. Carlos Alonso, who has been serving as interim CEO since October 2024, will ensure a smooth transition while continuing in the role of Executive Chairman. In a statement, Alonso expressed confidence in Mañé's deep industry knowledge and strategic mindset, believing they will significantly bolster Suanfarma's market position and enhance customer and partner solutions.

Mañé's appointment is expected to propel Suanfarma's growth trajectory. His emphasis on operational excellence, advanced CDMO capabilities, and robust strategic partnerships will guide the company as it embarks on its next chapter. Some of the key objectives under his leadership will include:

• - Streamlining industrial operations and integrating new technologies to enhance efficiency.
• - Strengthening relationships with global clients and key suppliers to foster collaboration.
• - Accelerating international expansion to tap into new markets and opportunities.
• - Promoting a culture of innovation and sustainability across the organization.

Reflecting on his new role, Pere Mañé stated, "Suanfarma has all the elements in place to lead the industry into the future—a solid foundation, a strong industrial platform, and a valuable international network supported by an exceptional team. I am eager to start this new chapter and work together to continue providing innovative, effective, and sustainable solutions for our clients."

About Suanfarma

Founded in 1993, Suanfarma is a B2B partner in the life sciences sector. The company is dedicated to health and innovation through sustainable development, manufacturing, and distribution of high-quality pharmaceutical ingredients. Operating in over 70 countries, Suanfarma has been part of the healthcare-focused investment firm Archimed since 2021, further reinforcing its commitment to advancing the pharmaceutical landscape.

Through Mañé's leadership, Suanfarma aims to enhance its operational capabilities, address evolving market demands, and contribute positively to the global healthcare framework, ensuring it remains at the forefront of the pharmaceutical industry.